S. 735Senate119th Congress (2025-2027)In Committee

Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Sponsored by Tim ScottSen. Tim Scott (R-SC)
Introduced February 26, 2025

AI-Generated Summary

Updated November 24, 2025 at 2:25 AM UTC

The bill amends the Public Health Service Act to reauthorize and expand a federal demonstration program focused on sickle cell disease. It broadens the program’s scope to treat the disease and its complications, gives the program flexibility to award grants or cooperative agreements, and raises its yearly budget to $8.2 million for the 2025‑2029 period. It also urges additional research into the causes and cures of hereditary blood disorders.

Key Provisions

  • Updates the program’s purpose to cover treatment of sickle cell disease and the prevention and treatment of its complications.
  • Allows the program to provide grants, contracts, or cooperative agreements rather than only contracts.
  • Increases annual funding to $8,205,000 for fiscal years 2025‑2029 (up from the previous $4,455,000 level).
  • Expresses Congress’s desire for more research into the causes and cures of heritable blood disorders, including sickle cell disease.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

1 earlier action
SenateIntro Referral Latest Action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

February 26, 2025

View full timeline
SenateIntro Referral

Introduced in Senate

February 26, 2025

SenateIntro Referral

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

February 26, 2025

Bill Text

Latest available legislative text

Reading Mode
Latest
Introduced in SenateIssued February 26, 2025

II

119th CONGRESS

1st Session

S. 735

IN THE SENATE OF THE UNITED STATES

February 26, 2025

Mr. Scott of South Carolina (for himself and Mr. Booker) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.

1.

Short title

This Act may be cited as the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025.

2.

Sickle cell disease prevention and treatment

(a)

In general

Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b–5(b)) is amended—

(1)

in paragraph (1)(A)(iii), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease;

(2)

in paragraph (2)(D), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease;

(3)

in paragraph (3)—

(A)

in subparagraph (A), by striking enter into a contract with and inserting make a grant to, or enter into a contract or cooperative agreement with,; and

(B)

in subparagraph (B), in each of clauses (ii) and (iii), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease; and

(4)

in paragraph (6), by striking $4,455,000 for each of fiscal years 2019 through 2023 and inserting $8,205,000 for each of fiscal years 2025 through 2029.

(b)

Sense of Congress

It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.